The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis
Open accessAbstract
BACKGROUND: Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of preventing restenosis. METHODS: We conducted a multicenter, randomized, controlled, triple-blind study to evaluate the ability of a paclitaxel-eluting stent to inhibit restenosis. At three centers, 177 patients with discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter) underwent implantation of paclitaxel-eluting stents (low dose, 1.3 microg per square millimeter, or high dose, 3.1 microg per square millimeter) or control stents. Antiplatelet therapies included aspirin with ticlopidine (120 patients), clopidogrel (18 patients), or cilostazol (37 patients). Clinical follow-up was performed at one month and four to six months, and angiographic follow-up at four to six months. RESULTS: Technical success was achieved in 99 percent of the patients (176 of 177). At follow-up, the high-dose group, as compared with the control group, had significantly better results for the degree of stenosis (mean [+/-SD], 14+/-21 percent vs. 39+/-27 percent; P<0.001), late loss of luminal diameter (0.29+/-0.72 mm vs. 1.04+/-0.83 mm, P<0.001), and restenosis of more than 50 percent (4 percent vs. 27 percent, P<0.001). Intravascular ultrasound analysis demonstrated a dose-dependent reduction in the volume of intimal hyperplasia (31, 18, and 13 mm3, in the high-dose, low-dose, and control groups, respectively). There was a higher rate of major cardiac events in patients receiving cilostazol than in those receiving ticlopidine or clopidogrel. Among patients receiving ticlopidine or clopidogrel, event-free survival was 98 percent and 100 percent in the high-dose and control groups, respectively, at one month, and 96 percent in both at four to six months. CONCLUSIONS: Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morice, M.-C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,033
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Patterns and Mechanisms of In-Stent Restenosis: A Serial Intravascular Ultrasound Study
Hoffmann, R., Mintz, G. S., Dussaillant, G. R., Popma, J. J., Pichard, A. D., Satler, L. F., Kent, K. M., Griffin, J., & Leon, M. B. (1996) · Circulation · doi:10.1161/01.cir.94.6.1247 · Cited by 1,247
Self-citationTaxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Axel, D. I., Kunert, W., Göggelmann, C., Oberhoff, M., Herdeg, C., Küttner, A., Wild, D. H., Brehm, B. R., Riessen, R., Köveker, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.2.636 · Cited by 784
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
Heldman, A. W., Cheng, L., Jenkins, G. M., Heller, P. F., Kim, D.-W., Ware, M., Nater, C., Hruban, R. H., Rezai, B., Abella, B. S., et al. (2001) · Circulation · doi:10.1161/01.cir.103.18.2289 · Cited by 435
Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent
Farb, A., Heller, P. F., Shroff, S., Cheng, L., Kolodgie, F. D., Carter, A. J., Scott, D. S., Froehlich, J., & Virmani, R. (2001) · Circulation · doi:10.1161/hc3001.092037 · Cited by 423
Cited by
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Colombo, A., Drzewiecki, J., Banning, A., Grube, E., Hauptmann, K., Silber, S., Dudek, D., Fort, S., Schiele, F., Zmudka, K., et al. (2003) · Circulation · doi:10.1161/01.cir.0000086926.62288.a6 · Cited by 1,016
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents
Babapulle, M. N., Joseph, L., Bélisle, P., Brophy, J. M., & Eisenberg, M. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16850-5 · Cited by 645
Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization
Windecker, S., Remondino, A., Eberli, F. R., Jüni, P., Räber, L., Wenaweser, P., Togni, M., Billinger, M., Tüller, D., Seiler, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051175 · Cited by 593
Metadata
- Authors
- Park, S.-J., Shim, W. H., Ho, D. S., Raizner, A. E., Park, S.-W., Hong, M.-K., Lee, C. W., Choi, D., Jang, Y., Lam, R., Weissman, N. J., & Mintz, G. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-17
- Volume
- 348
- Issue
- 16
- Pages
- 1537-1545
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2104337019
- Cited by
- 456
- References
- 17
- FWCI
- 73.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis. https://app.cochat.ai/papers/10.1056/nejmoa021007
- The paper
- Park, S.-J., Shim, W. H., Ho, D. S., Raizner, A. E., Park, S.-W., Hong, M.-K., Lee, C. W., Choi, D., Jang, Y., Lam, R., Weissman, N. J., & Mintz, G. S. (2003). A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa021007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.